Opthea Ltd. ADR (OPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
OPT Stock Summary
- The ratio of debt to operating expenses for OPTHEA LTD is higher than it is for about only 4.37% of US stocks.
- With a year-over-year growth in debt of -85.92%, OPTHEA LTD's debt growth rate surpasses merely 2.39% of about US stocks.
- As for revenue growth, note that OPT's revenue has grown -286.73% over the past 12 months; that beats the revenue growth of only 0.09% of US companies in our set.
- Stocks that are quantitatively similar to OPT, based on their financial statements, market capitalization, and price volatility, are HIMX, HCM, CANF, ERYP, and OGEN.
- To dig deeper into the stock's financial statements, go to OPT's page on browse-edgar?action=getcompany&CIK=0001815620.
OPT Stock Price Chart Interactive Chart >
OPT Price/Volume Stats
| Current price | $5.80 | 52-week high | $8.50 |
| Prev. close | $6.13 | 52-week low | $4.73 |
| Day low | $5.78 | Volume | 13,620 |
| Day high | $6.19 | Avg. volume | 4,658 |
| 50-day MA | $6.34 | Dividend yield | N/A |
| 200-day MA | $6.53 | Market Cap | 294.20M |
Opthea Ltd. ADR (OPT) Company Bio
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
Latest OPT News From Around the Web
Below are the latest news stories about OPTHEA LTD that investors may wish to consider to help them evaluate OPT as an investment opportunity.
Here's Why Opthea (ASX:OPT) Must Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Opthea Reports Fiscal Year 2022 Financial Results and Corporate HighlightsSecured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations with appointment of C-Suite Executives Elected Mr. Quinton Oswald and Dr. Susan Orr to Board of Directors MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and pro |
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferenceMELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Chief Executive Officer Dr. Megan Baldwin will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference, taking place virtually on August 17, 2022. The presentation will be made available at 7:00 AM ET (9:00 PM AET) and may be accessed for 90 |
Opthea Successfully Closes Well Supported US$90 Million Equity FinancingMELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to confirm it has received binding commitments for a successful two-tranche placement (Placement) of new fully paid ordinary shares (New Shares) to institutional investors to raise approximately US$90 million1 (A$128.57 million) at a price of A$1.15 per N |
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMDCarlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M, consisting of a US$120M commitment and an option to increase funding by a further US$50MIf OPT-302 is approved in a major market, Carlyle and Abingworth will be eligible to receive fixed success payments and variable success payments of 7% on annual net sales, which terminate after reaching four times the f |
OPT Price Returns
| 1-mo | -1.44% |
| 3-mo | -10.77% |
| 6-mo | -9.38% |
| 1-year | -27.86% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -23.13% |
| 2021 | -32.72% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...